Biotest Stock
Key metrics
Is Biotest a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.
Biotest Stock Analysis
Analyst Opinions
7 Analysts have issued a Biotest forecast:
Analyst Opinions
7 Analysts have issued a Biotest forecast:
Financial data from Biotest
| Mar '25 |
+/-
%
|
||
| Revenue | 635 635 |
16%
16%
|
|
| Gross Profit | 147 147 |
54%
54%
|
|
| EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | 12 12 |
93%
93%
|
| Net Profit | -25 -25 |
116%
116%
|
|
In millions EUR.
Don't miss a Thing! We will send you all news about Biotest directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biotest Stock News
Company Profile
Biotest AG engages in the development, manufacture, and marketing of plasma proteins and biotherapeutic drugs. It operates through the following segments: Therapy, Plasma and Services, and Other. The Therapy segment develops and produces blood plasma-based immunoglobulins, clotting factors, and albumins which are used to treat diseases of the immune system, haematological diseases, and in intensive care medicine. The Plasma and Services segment includes the areas of plasma sales and contract manufacturing. The Other segment refers to the merchandise business. The company was founded by Carl Adolf Schleussner and Hans Schleussner in 1946 and is headquartered in Dreieich, Germany.
| Head office | Germany |
| CEO | Peter Janssen |
| Employees | 2,495 |
| Founded | 1946 |
| Website | www.biotest.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
